Novo Nordisk

Slipping expectations frustrate investors again and again

12/02/26 -"Since the beginning of 2025, and even after the new CEO (Maziar Mike Doustdar) was appointed in August 2025, Novo has downgraded growth expectations multiple times, which raises questions as to how ..."

PDF page sample
Pages
72
Language
English
Published on
12/02/26
Download
You may also be interested by these reports :
12/02/26
Since the beginning of 2025, and even after the new CEO (Maziar Mike Doustdar) was appointed in August 2025, Novo has downgraded growth expectations ...
10/02/26
Even though Q4 25 operating profitability missed the street’s expectations, Astra met its full-year CER guidance. The Q4 performance was largely ...
06/02/26
Q4 ‘25 results exceeded consensus, as Lundbeck met its 2025 guidance. Strong growth for depression treatment Rexulti and migraine medicine Vyepti ...
05/02/26
The hugely discounted pricing announced by Hims & Hers for copycat pill versions of Novo’s semaglutide (for weight loss) seems perplexing, as they ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO